Altimmune, Inc. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2012 to Q1 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Altimmune, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2012 to Q1 2025.
- Altimmune, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2025 was -$681K.
- Altimmune, Inc. annual Deferred Income Tax Expense (Benefit) for 2019 was -$58.5K, a 99% increase from 2018.
- Altimmune, Inc. annual Deferred Income Tax Expense (Benefit) for 2018 was -$6.15M, a 135% decline from 2017.
- Altimmune, Inc. annual Deferred Income Tax Expense (Benefit) for 2017 was -$2.62M, a 4333% decline from 2016.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)